Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Day (March 2021)
13 slides from Astrazeneca's investor day presentation, Mar 25, 2021
Slide 1: New CVRM: near-term opportunities
Break-out session 2 New CVRM: near- term opportunities Elisabeth Björk, Senior Vice President, late-stage R&D John Houghton, Global Franchise Head, roxadustat, late- stage R&D Joris Silon, Senior Vice President, Head of CVRM, BioPharmaceuticals Business Unit 25 March 2021 Interactive event for inves
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’the Group’) provides the following cautionary statement: this document contains certain forward-looking statements wit
Slide 3: Farxiga
Farxiga Broad development programme beyond T2D1 DAPA-CKD Phase III (CKD3) Reduced the worsening of renal function or renal or CV4 death by 39%5 DAPA-HF Phase III (HFrEF) DECLARE Phase III (T2D) DAPA-HF Phase III (HFrEF2) Approved in US, EU, JP and CN Positive cardiorenal benefit 26% risk reduction F
Slide 4: Farxiga ~$2 billion
Farxiga $m New and upcoming milestones 600 DAPA-CKD Phase III (CKD) 500 Regulatory decision US (H1 2021) EU, JP, CN (H2 2021) zibotentan + Farxiga DELIVER Phase III (HFpEF1) AZD9977 + Farxiga 400 Data readout H2 2021 Data readout 300 200 2021 2022+ 100 NEW trials 0 Phase III DAPA-MI2 Achieved FPCD3
Slide 5: CKD affects c.840m adults worldwide
CKD affects c.840m adults worldwide Silent, progressive, high-mortality disease; significantly underdiagnosed 100 Anaemia prevalence by CKD stage, United States1 >2 billion People at risk of developing CKD2 80 % of patients 60 Approach c.840 million 40 20 0 Revolutionise: early Estimated people with
Slide 6: Lokelma
Lokelma Rapid and sustained potassium control for patients with hyperkalaemia HK1 is common in patients DIALIZE Phase IIIb trial FY2020: Global $76m; US $57m with chronic conditions2 $m • The first randomised, placebo- controlled trial of a K+ binder5 in 44% the treatment of HD6 patients 30 of patie
Slide 7: Roxadustat
Roxadustat1 Shifting the treatment paradigm for patients with anaemia from CKD Unique characteristics Key data from ASN6 2020 China $30m; focus on hospital $m listings and patient access • MACE7, MACE+8, and CV event rates were • Leverages the body’s natural response to lowest at achieved Hb levels
Slide 8: Full pipeline and news flow
Full pipeline and news flow Expanding Farxiga from T2D and HF to CKD New CVRM: near-term opportunities Upcoming milestones Phase II Phase III Regulatory review H1 2021 • Farxiga - CKD: regulatory decision (US) Farxiga DAPA-MI roxadustat1 Farxiga DAPA-CKD SGLT23 HIF-PH2 inhibitor SGLT2 chemo induced
Slide 9: Questions & Answers
Questions & Answers To ask a question Webinar Click ’Raise Hand’ (preferred): or type your question into the Q&A box (alternative) Phone *6 - Toggle mute/unmute *9 - Raise hand 9
Slide 10: Appendix
Appendix 10
Slide 11: Publications
Publications Farxiga Trial Journal Title Author Citation New England Journal of N Engl J Med 2020; DAPA-CKD Dapagliflozin in Patients with Chronic Kidney Disease Heerspink, H.J.L et al. Medicine 383:1436-1446 New England Journal of N Engl J Med 2019; DAPA-HF Dapagliflozin in Patients with Heart Fail
Slide 12: Publications, continued
Publications, continued Roxadustat Trial Journal Title Author Citation Journal of the American Society Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized JASN March OLYMPUS Fishbane, S et al. of Nephrology Phase 3 Study 2021, 32 (3) 737-755 Kidney Internat
Slide 13: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availabl